Patients and methods. Vaccination using the 7-and 13-valent It should also be taken into account that the highest level of severe disease forms and fatal outcomes is registered in the aforementioned risk groups [6] . Treatment of this category of patients is extremely expensive.
INTRODUCTION
Pneumococcal infections in younger children pose a formidable global problem of public health.
It is well known that Streptococcus pneumoniae (pneumococcus) may cause both severe invasive infections (meningites, invasive pneumoniae (sometimes with empyemata), sepsis (including occult bacteremia, i.e. fever with hidden infection nidus)) and less severe, yet much more frequent diseases, such as otites media, sinusites, pneumoniae and bronchites. The problem is the gravest in the group of 0-5-year-old children -it's estimated that the morbidity rate among them is 0.29 cases per child per year in the developing countries and 0.05 cases per child per year in the developed countries; 7-13% of cases of pneumococcal infection are severe and require hospitalization. The highest invasive pneumococcal infection morbidity risk is noted in risk groups, i.e. children, who are artificially fed from small age or insufficiently fed, with low birth weight (including premature infants) and those living in congested conditions [1] . Apart from the aforementioned, the World Health Organization also deems environmental pollution one of the risk factors increasing rate and severity of pneumococcal infections.
A big number of scientific works is dedicated to the anthropogenic pollution's influence on population health in our country. It has been revealed that ecological pressing considerably contributes to the morbidity rate (including infectious morbidity) [2, 3] due to the reduction in immune response in children living in polluted areas [4] . It is also known that the highest volumes of air pollutant emissions from stationary sources are in Ural, West and East Siberian economic regions (59% of all emissions in Russia). According to several authors, role of ecologic factor in children's health aggravation is indisputable. Industrial pollution of places of residence increases the chronic pathology level by 60%, including the level of respiratory diseases -by 67% [5] .
It should also be taken into account that the highest level of severe disease forms and fatal outcomes is registered in the aforementioned risk groups [6] . Treatment of this category of patients is extremely expensive.
Thus, as long as there is no cohort pneumococcal infection immunization in Russia, protection of risk group children is the first-priority task, which is why various territories of the Russian Federation are conducting pneumococcal infection vaccination programs for children with background pathology [7, 8] . Urgency of pneumococcal infection prevention in smaller children, especially in the invasive infection risk group children, is undoubted. This problem is especially urgent in territories with high level of environment pollution, such as Irkutsk.
Study aim: to study efficacy of pneumococcal infection vaccination at the expense of the Irkutsk municipal budget aimed at reducing infantile morbidity and mortality rate in 2011-2012.
PATIENTS AND METHODS

Study participants
In order to study safety and efficacy of the pneumococcal infection vaccinal prevention of risk group children using the conjugated vaccine, we observed 193 children of the following age groups (age at the time of vaccination beginning):
• 2-6 months -66 (34.2%) children;
• 7-11 months -63 (32.6%);
• 12-23 months -35 (18.1%);
• over 24 months -29 (15%) children.
Study inclusion criteria were the following diseases (conditions): prematurity, congenital heart diseases (CHD), bronchopulmonary dysplasia, resuscitation measures in anamnesis.
Study methods
Vaccination efficacy and safety were appraised by analyzing outpatient cards of the vaccinated children throughout the observation period (18 months). Children were actively visited in the post-vaccinal period the following day after vaccination; later, children's condition was controlled by means of telephone survey of parents.
Initially, vaccination of 2-6-month-old children was conducted according to the Prevenar vaccine instructions using the scheme 3+1; in 7-11-month old children -2+1; in 12-23-month-old children -1+1. Children over 24 months of age received vaccine only once. However, due to the shortage of vaccine in 2012 children of 2-6 months of age were vaccinated using the scheme 2+1 [9] .
Statistical data manipulation
Statistical manipulation of results was conducting using non-parametric criteria (small sample and lack of normal distribution). We used criterion z; the calculation was conducted using the program "Biostatistics".
STUDY RESULTS AND DISCUSSION
One of the main goals of the departmental task program "Improvement of the medical- It should be noted that, according to the statistical data, share of premature infants at Irkutsk maternity hospitals every year is ca. 7% (in 2010 -6.7%); 85% of children out of them have a concurrent respiratory pathology (distress-syndrome and/or pneumonia). 5% of premature infants have indications to artificial pulmonary ventilation. Ca. 50-70 children are annually born with CHD.
As the stated group of children is rather numerous, amount of budgetary funds directed to execute the priority preventive measure, i.e. pneumococcal infection vaccination, was 30% of the total amount of vaccine purchase financing.
It is evident that the stated funds did not allow conducting pneumococcal infection vaccinal prevention to risk group children to the required extent, which is why it was decided to start a cofinancing program, i.e. it was planned to conduct the 2 nd and the 3 rd conjugated vaccine's administration at the expense of insurance companies or people's personal funds. Thus, a fullscale and effective pneumococcal infection immune prevention was ensured among the risk group children; the estimated vaccination coverage in the first stages of the program's fulfillment was to be not less than 75% of children of the aforementioned groups.
The total amount of purchased Prevenar vaccine (7-and 13-valent) doses in 2011 at the expense of the city budget and medical insurance companies was 507. 600 Prevenar 13 vaccine doses were purchased in 2012 at the expense of the municipal budget.
Diseases, which distinguished children into the risk group, are given in tb. 1 and 2.
Despite the opinion of several pediatricians that it is extremely difficult to vaccinate children with low and extremely low birth weight in the first half-year of life, 41% of premature infants in our study were vaccinated against pneumococcal infection before 6 months of age (pic. 1). It is safe to vaccinate the risk group children with both 7-and 13-valent conjugated pneumococcal vaccine, including combination with other national calendar's vaccines.
Pic. 1. PCV7 and PCV13 vaccination beginning in premature infants (%)
In order to achieve epidemiologically significant reduction in the rate of diseases caused by S.
pneumoniae, it is necessary to conduct cohort immunization of children of the first year of life (preferably, from 2 months of age).
Cohort vaccinal prevention is the most available, economical and effective means of fighting pneumococcal infection; there is an unconditional need in introducing vaccination against S.
pneumonia into the national vaccination calendar in Russia as in 52 other countries. 
